

SENATE SUBSTITUTE  
FOR  
SENATE COMMITTEE SUBSTITUTE  
FOR  
SENATE BILL NO. 826

AN ACT

To repeal sections 195.010, 195.070, 195.080, and 338.010, RSMo, and to enact in lieu thereof five new sections relating to pharmacy, with an emergency clause for a certain section.

---

---

BE IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF MISSOURI,  
AS FOLLOWS:

1           Section A. Sections 195.010, 195.070, 195.080, and 338.010,  
2 RSMo, are repealed and five new sections enacted in lieu thereof,  
3 to be known as sections 195.010, 195.070, 195.080, 195.265, and  
4 338.010, to read as follows:

5           195.010. The following words and phrases as used in this  
6 chapter and chapter 579, unless the context otherwise requires,  
7 mean:

8           (1) "Acute pain", pain, whether resulting from disease,  
9 accidental or intentional trauma, or other causes, that the  
10 practitioner reasonably expects to last only a short period of  
11 time. "Acute pain" shall not include chronic pain, pain being  
12 treated as part of cancer care, hospice or other end of life  
13 care, or medication-assisted treatment for substance use  
14 disorders;

15           (2) "Addict", a person who habitually uses one or more  
16 controlled substances to such an extent as to create a tolerance

1 for such drugs, and who does not have a medical need for such  
2 drugs, or who is so far addicted to the use of such drugs as to  
3 have lost the power of self-control with reference to his or her  
4 addiction;

5 [(2)] (3) "Administer", to apply a controlled substance,  
6 whether by injection, inhalation, ingestion, or any other means,  
7 directly to the body of a patient or research subject by:

8 (a) A practitioner (or, in his or her presence, by his or  
9 her authorized agent); or

10 (b) The patient or research subject at the direction and in  
11 the presence of the practitioner;

12 [(3)] (4) "Agent", an authorized person who acts on behalf  
13 of or at the direction of a manufacturer, distributor, or  
14 dispenser. The term does not include a common or contract  
15 carrier, public warehouseman, or employee of the carrier or  
16 warehouseman while acting in the usual and lawful course of the  
17 carrier's or warehouseman's business;

18 [(4)] (5) "Attorney for the state", any prosecuting  
19 attorney, circuit attorney, or attorney general authorized to  
20 investigate, commence and prosecute an action under this chapter;

21 [(5)] (6) "Controlled substance", a drug, substance, or  
22 immediate precursor in Schedules I through V listed in this  
23 chapter;

24 [(6)] (7) "Controlled substance analogue", a substance the  
25 chemical structure of which is substantially similar to the  
26 chemical structure of a controlled substance in Schedule I or II  
27 and:

28 (a) Which has a stimulant, depressant, or hallucinogenic

1 effect on the central nervous system substantially similar to the  
2 stimulant, depressant, or hallucinogenic effect on the central  
3 nervous system of a controlled substance included in Schedule I  
4 or II; or

5 (b) With respect to a particular individual, which that  
6 individual represents or intends to have a stimulant, depressant,  
7 or hallucinogenic effect on the central nervous system  
8 substantially similar to the stimulant, depressant, or  
9 hallucinogenic effect on the central nervous system of a  
10 controlled substance included in Schedule I or II. The term does  
11 not include a controlled substance; any substance for which there  
12 is an approved new drug application; any substance for which an  
13 exemption is in effect for investigational use, for a particular  
14 person, under Section 505 of the federal Food, Drug and Cosmetic  
15 Act (21 U.S.C. Section 355) to the extent conduct with respect to  
16 the substance is pursuant to the exemption; or any substance to  
17 the extent not intended for human consumption before such an  
18 exemption takes effect with respect to the substance;

19 [(7)] (8) "Counterfeit substance", a controlled substance  
20 which, or the container or labeling of which, without  
21 authorization, bears the trademark, trade name, or other  
22 identifying mark, imprint, number or device, or any likeness  
23 thereof, of a manufacturer, distributor, or dispenser other than  
24 the person who in fact manufactured, distributed, or dispensed  
25 the substance;

26 [(8)] (9) "Deliver" or "delivery", the actual,  
27 constructive, or attempted transfer from one person to another of  
28 drug paraphernalia or of a controlled substance, or an imitation

1 controlled substance, whether or not there is an agency  
2 relationship, and includes a sale;

3 [(9)] (10) "Dentist", a person authorized by law to  
4 practice dentistry in this state;

5 [(10)] (11) "Depressant or stimulant substance":

6 (a) A drug containing any quantity of barbituric acid or  
7 any of the salts of barbituric acid or any derivative of  
8 barbituric acid which has been designated by the United States  
9 Secretary of Health and Human Services as habit forming under 21  
10 U.S.C. Section 352(d);

11 (b) A drug containing any quantity of:

12 a. Amphetamine or any of its isomers;

13 b. Any salt of amphetamine or any salt of an isomer of  
14 amphetamine; or

15 c. Any substance the United States Attorney General, after  
16 investigation, has found to be, and by regulation designated as,  
17 habit forming because of its stimulant effect on the central  
18 nervous system;

19 (c) Lysergic acid diethylamide; or

20 (d) Any drug containing any quantity of a substance that  
21 the United States Attorney General, after investigation, has  
22 found to have, and by regulation designated as having, a  
23 potential for abuse because of its depressant or stimulant effect  
24 on the central nervous system or its hallucinogenic effect;

25 [(11)] (12) "Dispense", to deliver a narcotic or controlled  
26 dangerous drug to an ultimate user or research subject by or  
27 pursuant to the lawful order of a practitioner including the  
28 prescribing, administering, packaging, labeling, or compounding

1 necessary to prepare the substance for such delivery.

2 "Dispenser" means a practitioner who dispenses;

3 [(12)] (13) "Distribute", to deliver other than by  
4 administering or dispensing a controlled substance;

5 [(13)] (14) "Distributor", a person who distributes;

6 [(14)] (15) "Drug":

7 (a) Substances recognized as drugs in the official United  
8 States Pharmacopoeia, Official Homeopathic Pharmacopoeia of the  
9 United States, or Official National Formulary, or any supplement  
10 to any of them;

11 (b) Substances intended for use in the diagnosis, cure,  
12 mitigation, treatment or prevention of disease in humans or  
13 animals;

14 (c) Substances, other than food, intended to affect the  
15 structure or any function of the body of humans or animals; and

16 (d) Substances intended for use as a component of any  
17 article specified in this subdivision. It does not include  
18 devices or their components, parts or accessories;

19 [(15)] (16) "Drug-dependent person", a person who is using  
20 a controlled substance and who is in a state of psychic or  
21 physical dependence, or both, arising from the use of such  
22 substance on a continuous basis. Drug dependence is  
23 characterized by behavioral and other responses which include a  
24 strong compulsion to take the substance on a continuous basis in  
25 order to experience its psychic effects or to avoid the  
26 discomfort caused by its absence;

27 [(16)] (17) "Drug enforcement agency", the Drug Enforcement  
28 Administration in the United States Department of Justice, or its

1 successor agency;

2 [(17)] (18) "Drug paraphernalia", all equipment, products,  
3 substances and materials of any kind which are used, intended for  
4 use, or designed for use, in planting, propagating, cultivating,  
5 growing, harvesting, manufacturing, compounding, converting,  
6 producing, processing, preparing, storing, containing,  
7 concealing, injecting, ingesting, inhaling, or otherwise  
8 introducing into the human body a controlled substance or an  
9 imitation controlled substance in violation of this chapter or  
10 chapter 579. It includes, but is not limited to:

11 (a) Kits used, intended for use, or designed for use in  
12 planting, propagating, cultivating, growing or harvesting of any  
13 species of plant which is a controlled substance or from which a  
14 controlled substance can be derived;

15 (b) Kits used, intended for use, or designed for use in  
16 manufacturing, compounding, converting, producing, processing, or  
17 preparing controlled substances or imitation controlled  
18 substances;

19 (c) Isomerization devices used, intended for use, or  
20 designed for use in increasing the potency of any species of  
21 plant which is a controlled substance or an imitation controlled  
22 substance;

23 (d) Testing equipment used, intended for use, or designed  
24 for use in identifying, or in analyzing the strength,  
25 effectiveness or purity of controlled substances or imitation  
26 controlled substances;

27 (e) Scales and balances used, intended for use, or designed  
28 for use in weighing or measuring controlled substances or

1 imitation controlled substances;

2 (f) Dilutents and adulterants, such as quinine  
3 hydrochloride, mannitol, mannite, dextrose and lactose, used,  
4 intended for use, or designed for use in cutting controlled  
5 substances or imitation controlled substances;

6 (g) Separation gins and sifters used, intended for use, or  
7 designed for use in removing twigs and seeds from, or in  
8 otherwise cleaning or refining, marijuana;

9 (h) Blenders, bowls, containers, spoons and mixing devices  
10 used, intended for use, or designed for use in compounding  
11 controlled substances or imitation controlled substances;

12 (i) Capsules, balloons, envelopes and other containers  
13 used, intended for use, or designed for use in packaging small  
14 quantities of controlled substances or imitation controlled  
15 substances;

16 (j) Containers and other objects used, intended for use, or  
17 designed for use in storing or concealing controlled substances  
18 or imitation controlled substances;

19 (k) Hypodermic syringes, needles and other objects used,  
20 intended for use, or designed for use in parenterally injecting  
21 controlled substances or imitation controlled substances into the  
22 human body;

23 (l) Objects used, intended for use, or designed for use in  
24 ingesting, inhaling, or otherwise introducing marijuana, cocaine,  
25 hashish, or hashish oil into the human body, such as:

26 a. Metal, wooden, acrylic, glass, stone, plastic, or  
27 ceramic pipes with or without screens, permanent screens, hashish  
28 heads, or punctured metal bowls;

- 1           b. Water pipes;
- 2           c. Carburetion tubes and devices;
- 3           d. Smoking and carburetion masks;
- 4           e. Roach clips meaning objects used to hold burning
- 5 material, such as a marijuana cigarette, that has become too
- 6 small or too short to be held in the hand;
- 7           f. Miniature cocaine spoons and cocaine vials;
- 8           g. Chamber pipes;
- 9           h. Carburetor pipes;
- 10          i. Electric pipes;
- 11          j. Air-driven pipes;
- 12          k. Chillums;
- 13          l. Bonges;
- 14          m. Ice pipes or chillers;
- 15          (m) Substances used, intended for use, or designed for use
- 16 in the manufacture of a controlled substance;

17  
18 In determining whether an object, product, substance or material  
19 is drug paraphernalia, a court or other authority should  
20 consider, in addition to all other logically relevant factors,  
21 the following:

- 22          a. Statements by an owner or by anyone in control of the
- 23 object concerning its use;
- 24          b. Prior convictions, if any, of an owner, or of anyone in
- 25 control of the object, under any state or federal law relating to
- 26 any controlled substance or imitation controlled substance;
- 27          c. The proximity of the object, in time and space, to a
- 28 direct violation of this chapter or chapter 579;



1           d. The proximity of the object to controlled substances or  
2 imitation controlled substances;

3           e. The existence of any residue of controlled substances or  
4 imitation controlled substances on the object;

5           f. Direct or circumstantial evidence of the intent of an  
6 owner, or of anyone in control of the object, to deliver it to  
7 persons who he or she knows, or should reasonably know, intend to  
8 use the object to facilitate a violation of this chapter or  
9 chapter 579; the innocence of an owner, or of anyone in control  
10 of the object, as to direct violation of this chapter or chapter  
11 579 shall not prevent a finding that the object is intended for  
12 use, or designed for use as drug paraphernalia;

13           g. Instructions, oral or written, provided with the object  
14 concerning its use;

15           h. Descriptive materials accompanying the object which  
16 explain or depict its use;

17           i. National or local advertising concerning its use;

18           j. The manner in which the object is displayed for sale;

19           k. Whether the owner, or anyone in control of the object,  
20 is a legitimate supplier of like or related items to the  
21 community, such as a licensed distributor or dealer of tobacco  
22 products;

23           l. Direct or circumstantial evidence of the ratio of sales  
24 of the object to the total sales of the business enterprise;

25           m. The existence and scope of legitimate uses for the  
26 object in the community;

27           n. Expert testimony concerning its use;

28           o. The quantity, form or packaging of the product,

1 substance or material in relation to the quantity, form or  
2 packaging associated with any legitimate use for the product,  
3 substance or material;

4 [(18)] (19) "Federal narcotic laws", the laws of the United  
5 States relating to controlled substances;

6 [(19)] (20) "Hospital", a place devoted primarily to the  
7 maintenance and operation of facilities for the diagnosis,  
8 treatment or care, for not less than twenty-four hours in any  
9 week, of three or more nonrelated individuals suffering from  
10 illness, disease, injury, deformity or other abnormal physical  
11 conditions; or a place devoted primarily to provide, for not less  
12 than twenty-four consecutive hours in any week, medical or  
13 nursing care for three or more nonrelated individuals. The term  
14 "hospital" does not include convalescent, nursing, shelter or  
15 boarding homes as defined in chapter 198;

16 [(20)] (21) "Immediate precursor", a substance which:

17 (a) The state department of health and senior services has  
18 found to be and by rule designates as being the principal  
19 compound commonly used or produced primarily for use in the  
20 manufacture of a controlled substance;

21 (b) Is an immediate chemical intermediary used or likely to  
22 be used in the manufacture of a controlled substance; and

23 (c) The control of which is necessary to prevent, curtail  
24 or limit the manufacture of the controlled substance;

25 [(21)] (22) "Imitation controlled substance", a substance  
26 that is not a controlled substance, which by dosage unit  
27 appearance (including color, shape, size and markings), or by  
28 representations made, would lead a reasonable person to believe

1 that the substance is a controlled substance. In determining  
2 whether the substance is an imitation controlled substance the  
3 court or authority concerned should consider, in addition to all  
4 other logically relevant factors, the following:

5 (a) Whether the substance was approved by the federal Food  
6 and Drug Administration for over-the-counter (nonprescription or  
7 nonlegend) sales and was sold in the federal Food and Drug  
8 Administration approved package, with the federal Food and Drug  
9 Administration approved labeling information;

10 (b) Statements made by an owner or by anyone else in  
11 control of the substance concerning the nature of the substance,  
12 or its use or effect;

13 (c) Whether the substance is packaged in a manner normally  
14 used for illicit controlled substances;

15 (d) Prior convictions, if any, of an owner, or anyone in  
16 control of the object, under state or federal law related to  
17 controlled substances or fraud;

18 (e) The proximity of the substances to controlled  
19 substances;

20 (f) Whether the consideration tendered in exchange for the  
21 noncontrolled substance substantially exceeds the reasonable  
22 value of the substance considering the actual chemical  
23 composition of the substance and, where applicable, the price at  
24 which over-the-counter substances of like chemical composition  
25 sell. An imitation controlled substance does not include a  
26 placebo or registered investigational drug either of which was  
27 manufactured, distributed, possessed or delivered in the ordinary  
28 course of professional practice or research;

1            [(22)] (23) "Initial prescription", a prescription issued  
2 to a patient who has never previously been issued a prescription  
3 for the drug or its pharmaceutical equivalent or who was  
4 previously issued a prescription for the drug or its  
5 pharmaceutical equivalent, but the date on which the current  
6 prescription is being issued is more than five months after the  
7 date the patient last used or was administered the drug or its  
8 equivalent;

9            (24) "Laboratory", a laboratory approved by the department  
10 of health and senior services as proper to be entrusted with the  
11 custody of controlled substances but does not include a  
12 pharmacist who compounds controlled substances to be sold or  
13 dispensed on prescriptions;

14            [(23)] (25) "Manufacture", the production, preparation,  
15 propagation, compounding or processing of drug paraphernalia or  
16 of a controlled substance, or an imitation controlled substance,  
17 either directly or by extraction from substances of natural  
18 origin, or independently by means of chemical synthesis, or by a  
19 combination of extraction and chemical synthesis, and includes  
20 any packaging or repackaging of the substance or labeling or  
21 relabeling of its container. This term does not include the  
22 preparation or compounding of a controlled substance or an  
23 imitation controlled substance or the preparation, compounding,  
24 packaging or labeling of a narcotic or dangerous drug:

25            (a) By a practitioner as an incident to his or her  
26 administering or dispensing of a controlled substance or an  
27 imitation controlled substance in the course of his or her  
28 professional practice, or

1 (b) By a practitioner or his or her authorized agent under  
2 his or her supervision, for the purpose of, or as an incident to,  
3 research, teaching or chemical analysis and not for sale;

4 [(24)] (26) "Marijuana", all parts of the plant genus  
5 Cannabis in any species or form thereof, including, but not  
6 limited to Cannabis Sativa L., Cannabis Indica, Cannabis  
7 Americana, Cannabis Ruderalis, and Cannabis Gigantea, whether  
8 growing or not, the seeds thereof, the resin extracted from any  
9 part of the plant; and every compound, manufacture, salt,  
10 derivative, mixture, or preparation of the plant, its seeds or  
11 resin. It does not include the mature stalks of the plant, fiber  
12 produced from the stalks, oil or cake made from the seeds of the  
13 plant, any other compound, manufacture, salt, derivative, mixture  
14 or preparation of the mature stalks (except the resin extracted  
15 therefrom), fiber, oil or cake, or the sterilized seed of the  
16 plant which is incapable of germination;

17 [(25)] (27) "Methamphetamine precursor drug", any drug  
18 containing ephedrine, pseudoephedrine, phenylpropanolamine, or  
19 any of their salts, optical isomers, or salts of optical isomers;

20 [(26)] (28) "Narcotic drug", any of the following, whether  
21 produced directly or indirectly by extraction from substances of  
22 vegetable origin, or independently by means of chemical  
23 synthesis, or by a combination of extraction and chemical  
24 analysis:

25 (a) Opium, opiate, and any derivative, of opium or opiate,  
26 including their isomers, esters, ethers, salts, and salts of  
27 isomers, esters, and ethers, whenever the existence of the  
28 isomers, esters, ethers, and salts is possible within the

1 specific chemical designation. The term does not include the  
2 isoquinoline alkaloids of opium;

3 (b) Coca leaves, but not including extracts of coca leaves  
4 from which cocaine, ecgonine, and derivatives of ecgonine or  
5 their salts have been removed;

6 (c) Cocaine or any salt, isomer, or salt of isomer thereof;

7 (d) Ecgonine, or any derivative, salt, isomer, or salt of  
8 isomer thereof;

9 (e) Any compound, mixture, or preparation containing any  
10 quantity of any substance referred to in paragraphs (a) to (d) of  
11 this subdivision;

12 [(27)] (29) "Official written order", an order written on a  
13 form provided for that purpose by the United States Commissioner  
14 of Narcotics, under any laws of the United States making  
15 provision therefor, if such order forms are authorized and  
16 required by federal law, and if no such order form is provided,  
17 then on an official form provided for that purpose by the  
18 department of health and senior services;

19 [(28)] (30) "Opiate" or "opioid", any substance having an  
20 addiction-forming or addiction-sustaining liability similar to  
21 morphine or being capable of conversion into a drug having  
22 addiction-forming or addiction-sustaining liability. The term  
23 includes its racemic and levorotatory forms. It does not  
24 include, unless specifically controlled under section 195.017,  
25 the dextrorotatory isomer of 3-methoxy-n-methyl-morphinan and its  
26 salts (dextromethorphan);

27 [(29)] (31) "Opium poppy", the plant of the species *Papaver*  
28 *somniferum* L., except its seeds;

1            [(30)] (32) "Over-the-counter sale", a retail sale licensed  
2 pursuant to chapter 144 of a drug other than a controlled  
3 substance;

4            [(31)] (33) "Person", an individual, corporation,  
5 government or governmental subdivision or agency, business trust,  
6 estate, trust, partnership, joint venture, association, or any  
7 other legal or commercial entity;

8            [(32)] (34) "Pharmacist", a licensed pharmacist as defined  
9 by the laws of this state, and where the context so requires, the  
10 owner of a store or other place of business where controlled  
11 substances are compounded or dispensed by a licensed pharmacist;  
12 but nothing in this chapter shall be construed as conferring on a  
13 person who is not registered nor licensed as a pharmacist any  
14 authority, right or privilege that is not granted to him by the  
15 pharmacy laws of this state;

16           [(33)] (35) "Poppy straw", all parts, except the seeds, of  
17 the opium poppy, after mowing;

18           [(34)] (36) "Possessed" or "possessing a controlled  
19 substance", a person, with the knowledge of the presence and  
20 nature of a substance, has actual or constructive possession of  
21 the substance. A person has actual possession if he has the  
22 substance on his or her person or within easy reach and  
23 convenient control. A person who, although not in actual  
24 possession, has the power and the intention at a given time to  
25 exercise dominion or control over the substance either directly  
26 or through another person or persons is in constructive  
27 possession of it. Possession may also be sole or joint. If one  
28 person alone has possession of a substance possession is sole.

1 If two or more persons share possession of a substance,  
2 possession is joint;

3 [(35)] (37) "Practitioner", a physician, dentist,  
4 optometrist, podiatrist, veterinarian, scientific investigator,  
5 pharmacy, hospital or other person licensed, registered or  
6 otherwise permitted by this state to distribute, dispense,  
7 conduct research with respect to or administer or to use in  
8 teaching or chemical analysis, a controlled substance in the  
9 course of professional practice or research in this state, or a  
10 pharmacy, hospital or other institution licensed, registered, or  
11 otherwise permitted to distribute, dispense, conduct research  
12 with respect to or administer a controlled substance in the  
13 course of professional practice or research;

14 [(36)] (38) "Production", includes the manufacture,  
15 planting, cultivation, growing, or harvesting of drug  
16 paraphernalia or of a controlled substance or an imitation  
17 controlled substance;

18 [(37)] (39) "Registry number", the number assigned to each  
19 person registered under the federal controlled substances laws;

20 [(38)] (40) "Sale", includes barter, exchange, or gift, or  
21 offer therefor, and each such transaction made by any person,  
22 whether as principal, proprietor, agent, servant or employee;

23 [(39)] (41) "State" when applied to a part of the United  
24 States, includes any state, district, commonwealth, territory,  
25 insular possession thereof, and any area subject to the legal  
26 authority of the United States of America;

27 [(40)] (42) "Synthetic cannabinoid", includes unless  
28 specifically excepted or unless listed in another schedule, any



1 natural or synthetic material, compound, mixture, or preparation  
2 that contains any quantity of a substance that is a cannabinoid  
3 receptor agonist, including but not limited to any substance  
4 listed in paragraph (11) of subdivision (4) of subsection 2 of  
5 section 195.017 and any analogues; homologues; isomers, whether  
6 optical, positional, or geometric; esters; ethers; salts; and  
7 salts of isomers, esters, and ethers, whenever the existence of  
8 the isomers, esters, ethers, or salts is possible within the  
9 specific chemical designation, however, it shall not include any  
10 approved pharmaceutical authorized by the United States Food and  
11 Drug Administration;

12 [(41)] (43) "Ultimate user", a person who lawfully  
13 possesses a controlled substance or an imitation controlled  
14 substance for his or her own use or for the use of a member of  
15 his or her household or immediate family, regardless of whether  
16 they live in the same household, or for administering to an  
17 animal owned by him or by a member of his or her household. For  
18 purposes of this section, the phrase "immediate family" means a  
19 husband, wife, parent, child, sibling, stepparent, stepchild,  
20 stepbrother, stepsister, grandparent, or grandchild;

21 [(42)] (44) "Wholesaler", a person who supplies drug  
22 paraphernalia or controlled substances or imitation controlled  
23 substances that he himself has not produced or prepared, on  
24 official written orders, but not on prescriptions.

25 195.070. 1. A physician, podiatrist, dentist, a registered  
26 optometrist certified to administer pharmaceutical agents as  
27 provided in section 336.220, or an assistant physician in  
28 accordance with section 334.037 or a physician assistant in

1 accordance with section 334.747 in good faith and in the course  
2 of his or her professional practice only, may prescribe,  
3 administer, and dispense controlled substances or he or she may  
4 cause the same to be administered or dispensed by an individual  
5 as authorized by statute.

6 2. An advanced practice registered nurse, as defined in  
7 section 335.016, but not a certified registered nurse anesthetist  
8 as defined in subdivision (8) of section 335.016, who holds a  
9 certificate of controlled substance prescriptive authority from  
10 the board of nursing under section 335.019 and who is delegated  
11 the authority to prescribe controlled substances under a  
12 collaborative practice arrangement under section 334.104 may  
13 prescribe any controlled substances listed in Schedules III, IV,  
14 and V of section 195.017, and may have restricted authority in  
15 Schedule II. Prescriptions for Schedule II medications  
16 prescribed by an advanced practice registered nurse who has a  
17 certificate of controlled substance prescriptive authority are  
18 restricted to only those medications containing hydrocodone.  
19 However, no such certified advanced practice registered nurse  
20 shall prescribe controlled substance for his or her own self or  
21 family. Schedule III narcotic controlled substance and Schedule  
22 II - hydrocodone prescriptions shall be limited to a one hundred  
23 twenty-hour supply without refill.

24 3. A veterinarian, in good faith and in the course of the  
25 veterinarian's professional practice only, and not for use by a  
26 human being, may prescribe, administer, and dispense controlled  
27 substances and the veterinarian may cause them to be administered  
28 by an assistant or orderly under his or her direction and

1 supervision.

2 4. A practitioner shall not accept any portion of a  
3 controlled substance unused by a patient, for any reason, if such  
4 practitioner did not originally dispense the drug. However,  
5 unused controlled substances may be accepted from ultimate  
6 consumers through collection receptacles, drug disposal boxes,  
7 and other means provided through drug take back programs by a  
8 Drug Enforcement Agency-authorized collector in accordance with  
9 federal regulations, even if the authorized collector did not  
10 originally dispense the drug. This subsection shall supercede  
11 and preempt any local ordinances or regulations, including any  
12 ordinances or regulations enacted by any political subdivision of  
13 the state, regarding the disposal of unused controlled  
14 substances.

15 5. An individual practitioner shall not prescribe or  
16 dispense a controlled substance for such practitioner's personal  
17 use except in a medical emergency.

18 195.080. 1. Except as otherwise provided in this chapter  
19 and chapter 579, this chapter and chapter 579 shall not apply to  
20 the following cases: prescribing, administering, dispensing or  
21 selling at retail of liniments, ointments, and other preparations  
22 that are susceptible of external use only and that contain  
23 controlled substances in such combinations of drugs as to prevent  
24 the drugs from being readily extracted from such liniments,  
25 ointments, or preparations, except that this chapter and chapter  
26 579 shall apply to all liniments, ointments, and other  
27 preparations that contain coca leaves in any quantity or  
28 combination.

1           2. Unless otherwise provided in sections 334.037, 334.104,  
2 and 334.747, a practitioner, other than a veterinarian, shall not  
3 issue an initial prescription for more than a seven-day supply of  
4 any opioid controlled substance upon the initial consultation and  
5 treatment of a patient for acute pain. Upon any subsequent  
6 consultation for the same pain, the practitioner may issue any  
7 appropriate renewal, refill, or new prescription in compliance  
8 with the general provisions of this chapter and chapter 579.  
9 Prior to issuing an initial prescription for an opioid controlled  
10 substance, a practitioner shall consult with the patient  
11 regarding the quantity of the opioid and the patient's option to  
12 fill the prescription in a lesser quantity and shall inform the  
13 patient of the risks associated with the opioid prescribed. If,  
14 in the professional medical judgment of the practitioner, more  
15 than a seven-day supply is required to treat the patient's acute  
16 pain, the practitioner may issue a prescription for the quantity  
17 needed to treat the patient; provided, that the practitioner  
18 shall document in the patient's medical record the condition  
19 triggering the necessity for more than a seven-day supply and  
20 that a nonopioid alternative was not appropriate to address the  
21 patient's condition. The provisions of this subsection shall not  
22 apply to prescriptions for opioid controlled substances for a  
23 patient who is currently undergoing treatment for cancer, is  
24 receiving hospice care from a hospice certified under chapter 197  
25 or palliative care, is a resident of a long-term care facility  
26 licensed under chapter 198, or is receiving treatment for  
27 substance abuse or opioid dependence.

28           3. Unless otherwise provided in this section, the quantity

1 of Schedule II controlled substances prescribed or dispensed at  
2 any one time shall be limited to a thirty-day supply. The  
3 quantity of Schedule III, IV or V controlled substances  
4 prescribed or dispensed at any one time shall be limited to a  
5 ninety-day supply and shall be prescribed and dispensed in  
6 compliance with the general provisions of this chapter and  
7 chapter 579. The supply limitations provided in this subsection  
8 may be increased up to three months if the physician describes on  
9 the prescription form or indicates via telephone, fax, or  
10 electronic communication to the pharmacy to be entered on or  
11 attached to the prescription form the medical reason for  
12 requiring the larger supply. The supply limitations provided in  
13 this subsection shall not apply if:

14 (1) The prescription is issued by a practitioner located in  
15 another state according to and in compliance with the applicable  
16 laws of that state and the United States and dispensed to a  
17 patient located in another state; or

18 (2) The prescription is dispensed directly to a member of  
19 the United States Armed Forces serving outside the United States.

20 [3.] 4. The partial filling of a prescription for a  
21 Schedule II substance is permissible as defined by regulation by  
22 the department of health and senior services.

23 195.265. By August 28, 2019, the department of health and  
24 senior services shall develop an education and awareness program  
25 regarding drug disposal, including controlled substances. The  
26 education and awareness program may include, but not be limited  
27 to:

28 (1) A web-based resource that:

1       (a) Describes available drug disposal options including  
2 take back, take back events, mailers, in-home disposal options  
3 that render a product safe from misuse, or any other methods that  
4 comply with state and federal laws and regulations, may reduce  
5 the availability of unused controlled substances, and may  
6 minimize the potential environmental impact of drug disposal;

7       (b) Provides a list of drug disposal take back sites, which  
8 may be sorted and searched by name or location;

9       (c) Provides a list of take back events in the state,  
10 including the date, time, and location information for each  
11 event; and

12       (d) Provides information for authorized collectors  
13 regarding state and federal requirements to comply with the  
14 provisions of subsection 4 of section 195.070; and

15       (2) Promotional activities designed to ensure consumer  
16 awareness of proper storage and disposal of prescription drugs,  
17 including controlled substances.

18       338.010. 1. The "practice of pharmacy" means the  
19 interpretation, implementation, and evaluation of medical  
20 prescription orders, including any legend drugs under 21 U.S.C.  
21 Section 353; receipt, transmission, or handling of such orders or  
22 facilitating the dispensing of such orders; the designing,  
23 initiating, implementing, and monitoring of a medication  
24 therapeutic plan as defined by the prescription order so long as  
25 the prescription order is specific to each patient for care by a  
26 pharmacist; the compounding, dispensing, labeling, and  
27 administration of drugs and devices pursuant to medical  
28 prescription orders and administration of viral influenza,

1 pneumonia, shingles, hepatitis A, hepatitis B, diphtheria,  
2 tetanus, pertussis, and meningitis vaccines by written protocol  
3 authorized by a physician for persons [twelve] seven years of age  
4 or [older as authorized by rule] the Centers for Disease Control  
5 and Prevention recommendations, whichever is higher, or the  
6 administration of pneumonia, shingles, hepatitis A, hepatitis B,  
7 diphtheria, tetanus, pertussis, [and] meningitis, and viral  
8 influenza vaccines by written protocol authorized by a physician  
9 for a specific patient as authorized by rule; the participation  
10 in drug selection according to state law and participation in  
11 drug utilization reviews; the proper and safe storage of drugs  
12 and devices and the maintenance of proper records thereof;  
13 consultation with patients and other health care practitioners,  
14 and veterinarians and their clients about legend drugs, about the  
15 safe and effective use of drugs and devices; and the offering or  
16 performing of those acts, services, operations, or transactions  
17 necessary in the conduct, operation, management and control of a  
18 pharmacy. No person shall engage in the practice of pharmacy  
19 unless he is licensed under the provisions of this chapter. This  
20 chapter shall not be construed to prohibit the use of auxiliary  
21 personnel under the direct supervision of a pharmacist from  
22 assisting the pharmacist in any of his or her duties. This  
23 assistance in no way is intended to relieve the pharmacist from  
24 his or her responsibilities for compliance with this chapter and  
25 he or she will be responsible for the actions of the auxiliary  
26 personnel acting in his or her assistance. This chapter shall  
27 also not be construed to prohibit or interfere with any legally  
28 registered practitioner of medicine, dentistry, or podiatry, or

1 veterinary medicine only for use in animals, or the practice of  
2 optometry in accordance with and as provided in sections 195.070  
3 and 336.220 in the compounding, administering, prescribing, or  
4 dispensing of his or her own prescriptions.

5 2. Any pharmacist who accepts a prescription order for a  
6 medication therapeutic plan shall have a written protocol from  
7 the physician who refers the patient for medication therapy  
8 services. The written protocol and the prescription order for a  
9 medication therapeutic plan shall come from the physician only,  
10 and shall not come from a nurse engaged in a collaborative  
11 practice arrangement under section 334.104, or from a physician  
12 assistant engaged in a supervision agreement under section  
13 334.735.

14 3. Nothing in this section shall be construed as to prevent  
15 any person, firm or corporation from owning a pharmacy regulated  
16 by sections 338.210 to 338.315, provided that a licensed  
17 pharmacist is in charge of such pharmacy.

18 4. Nothing in this section shall be construed to apply to  
19 or interfere with the sale of nonprescription drugs and the  
20 ordinary household remedies and such drugs or medicines as are  
21 normally sold by those engaged in the sale of general  
22 merchandise.

23 5. No health carrier as defined in chapter 376 shall  
24 require any physician with which they contract to enter into a  
25 written protocol with a pharmacist for medication therapeutic  
26 services.

27 6. This section shall not be construed to allow a  
28 pharmacist to diagnose or independently prescribe



1 pharmaceuticals.

2 7. The state board of registration for the healing arts,  
3 under section 334.125, and the state board of pharmacy, under  
4 section 338.140, shall jointly promulgate rules regulating the  
5 use of protocols for prescription orders for medication therapy  
6 services [and administration of viral influenza vaccines]. Such  
7 rules shall require protocols to include provisions allowing for  
8 timely communication between the pharmacist and the referring  
9 physician, and any other patient protection provisions deemed  
10 appropriate by both boards. In order to take effect, such rules  
11 shall be approved by a majority vote of a quorum of each board.  
12 Neither board shall separately promulgate rules regulating the  
13 use of protocols for prescription orders for medication therapy  
14 services [and administration of viral influenza vaccines]. Any  
15 rule or portion of a rule, as that term is defined in section  
16 536.010, that is created under the authority delegated in this  
17 section shall become effective only if it complies with and is  
18 subject to all of the provisions of chapter 536 and, if  
19 applicable, section 536.028. This section and chapter 536 are  
20 nonseverable and if any of the powers vested with the general  
21 assembly pursuant to chapter 536 to review, to delay the  
22 effective date, or to disapprove and annul a rule are  
23 subsequently held unconstitutional, then the grant of rulemaking  
24 authority and any rule proposed or adopted after August 28, 2007,  
25 shall be invalid and void.

26 8. The state board of pharmacy may grant a certificate of  
27 medication therapeutic plan authority to a licensed pharmacist  
28 who submits proof of successful completion of a board-approved

1 course of academic clinical study beyond a bachelor of science in  
2 pharmacy, including but not limited to clinical assessment  
3 skills, from a nationally accredited college or university, or a  
4 certification of equivalence issued by a nationally recognized  
5 professional organization and approved by the board of pharmacy.

6 9. Any pharmacist who has received a certificate of  
7 medication therapeutic plan authority may engage in the  
8 designing, initiating, implementing, and monitoring of a  
9 medication therapeutic plan as defined by a prescription order  
10 from a physician that is specific to each patient for care by a  
11 pharmacist.

12 10. Nothing in this section shall be construed to allow a  
13 pharmacist to make a therapeutic substitution of a pharmaceutical  
14 prescribed by a physician unless authorized by the written  
15 protocol or the physician's prescription order.

16 11. "Veterinarian", "doctor of veterinary medicine",  
17 "practitioner of veterinary medicine", "DVM", "VMD", "BVSe",  
18 "BVMS", "BSe (Vet Science)", "VMB", "MRCVS", or an equivalent  
19 title means a person who has received a doctor's degree in  
20 veterinary medicine from an accredited school of veterinary  
21 medicine or holds an Educational Commission for Foreign  
22 Veterinary Graduates (EDFVG) certificate issued by the American  
23 Veterinary Medical Association (AVMA).

24 12. In addition to other requirements established by the  
25 joint promulgation of rules by the board of pharmacy and the  
26 state board of registration for the healing arts:

27 (1) A pharmacist shall administer vaccines by protocol in  
28 accordance with treatment guidelines established by the Centers

1 for Disease Control and Prevention (CDC);

2 (2) A pharmacist who is administering a vaccine shall  
3 request a patient to remain in the pharmacy a safe amount of time  
4 after administering the vaccine to observe any adverse reactions.  
5 Such pharmacist shall have adopted emergency treatment protocols;

6 (3) In addition to other requirements by the board, a  
7 pharmacist shall receive additional training as required by the  
8 board and evidenced by receiving a certificate from the board  
9 upon completion, and shall display the certification in his or  
10 her pharmacy where vaccines are delivered.

11 13. A pharmacist shall inform the patient that the  
12 administration of the vaccine will be entered into the ShowMeVax  
13 system, as administered by the department of health and senior  
14 services. The patient shall attest to the inclusion of such  
15 information in the system by signing a form provided by the  
16 pharmacist. If the patient indicates that he or she does not  
17 want such information entered into the ShowMeVax system, the  
18 pharmacist shall provide a written report within fourteen days of  
19 administration of a vaccine to the patient's primary health care  
20 provider, if provided by the patient, containing:

- 21 (1) The identity of the patient;
- 22 (2) The identity of the vaccine or vaccines administered;
- 23 (3) The route of administration;
- 24 (4) The anatomic site of the administration;
- 25 (5) The dose administered; and
- 26 (6) The date of administration.

27 Section B. Because immediate action is necessary to allow  
28 for the safe disposal of unused pharmaceuticals, the repeal and

1 reenactment of section 195.070 of this act is deemed necessary  
2 for the immediate preservation of the public health, welfare,  
3 peace, and safety, and is hereby declared to be an emergency act  
4 within the meaning of the constitution, and the repeal and  
5 reenactment of section 195.070 of this act shall be in full force  
6 and effect upon its passage and approval.